title: Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes.
abstract: Doxorubicin (DXR) was encapsulated in long-circulating liposomes, composed of ganglioside GM1 (GM1)/distearoylphosphatidylcholine (DSPC)/cholesterol (CH) (0.13:1:1 in molar ratio) and sized to approximately 100 nm in mean diameter, with 98% entrapping efficiency by the transmembrane pH gradient method. Free DXR, DXR-DSPC/CH and DXR-GM1/DSPC/CH liposomes were injected intravenously into Colon 26 tumor-bearing Balb/c mice via the tail vein at a dose of 5.0 mg DXR/kg. DXR-GM1/DSPC/CH liposomes gave a higher blood level of the drug than did DXR-DSPC/CH liposomes or free DXR up to 24 hours after injection, and the area under the blood concentration-time curve (AUC) for DXR-GM1/DSPC/CH liposomes was 1.5 or 526 times higher than that for DXR-DSPC/CH liposomes or free DXR, respectively. DXR-GM1/DSPC/CH liposomes gave a decreased DXR concentration in the reticuloendothelial system (RES) of the liver and the spleen. Both liposomal formulations effectively reduced the DXR concentration in the heart as compared with that in the case of free DXR. At 6 hours after i.v. injection, DXR-GM1/DSPC/CH liposomes provided an approximately 3.3- or 9-fold higher peak DXR level in the tumor as compared with DXR-DSPC/CH liposomes or the free drug, respectively. These high tumor levels of DXR appear to reflect the prolonged residence time of the liposomes. The results suggest that encapsulation of DXR in GM1-bearing long-circulating liposomes will be useful for cancer chemotherapy.
authors.affiliation: Department of Pharmacy, Tokyo Medical College Hospital, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Unezaki
authors.forename: K
authors.initials: K
authors.lastname: Maruyama
authors.forename: O
authors.initials: O
authors.lastname: Ishida
authors.forename: N
authors.initials: N
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Iwatsuru
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000378:metabolism*; D002784:Cholesterol; D003110:Colonic Neoplasms / Q000378:metabolism*; D004317:Doxorubicin / Q000493:pharmacokinetics*; D004337:Drug Carriers; D004339:Drug Compounding; D005677:G(M1) Ganglioside / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010316:Particle Size; D010713:Phosphatidylcholines; D014018:Tissue Distribution
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D010713:Phosphatidylcholines; D005677:G(M1) Ganglioside; D004317:Doxorubicin; D002784:Cholesterol; C010942:1,2-distearoyllecithin